Evidence map›Paper›PMID 40971023›Full record

ArticleRheumatology and therapy2025

The Impact of Uncontrolled Gout on Healthcare Utilization and Health Outcomes for United States Veterans Affairs Patients.

Adriana Vargus, Corbyn M Gilmore, Jim M Koeller, Grace C Lee, Haridarshan Patel, Brian LaMoreaux, Xavier F Jones, Christopher R Frei

Abstract read
In one paragraph

Article in Rheumatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Adriana VargusDepartment of Pharmacotherapy and Translational Science, College of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA. avargus@utexas.edu.ORCID http://orcid.org/0009-0001-7133-4329
Corbyn M GilmoreDepartment of Pharmacotherapy and Translational Science, College of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA.ORCID http://orcid.org/0000-0003-3847-3674
Jim M KoellerDepartment of Pharmacotherapy and Translational Science, College of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA.ORCID http://orcid.org/0000-0002-8962-7453
Grace C LeeDepartment of Pharmacotherapy and Translational Science, College of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA.ORCID http://orcid.org/0000-0002-7653-3028
Haridarshan PatelAmgen Inc, Thousand Oaks, CA, USA.ORCID http://orcid.org/0000-0002-1827-5163
Brian LaMoreauxAmgen Inc, Thousand Oaks, CA, USA.ORCID http://orcid.org/0000-0001-7521-241X
Xavier F JonesDepartment of Pharmacotherapy and Translational Science, College of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA.
Christopher R FreiDepartment of Pharmacotherapy and Translational Science, College of Pharmacy, The University of Texas at Austin, San Antonio, TX, USA.ORCID http://orcid.org/0000-0002-0692-4787

Funding

Institute for Integration of Medicine & Science: A Partnership to Improve HealthUM1TR004538 · NCATS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI ROBERT A CLARK, Kenneth M Hargreaves · 2023 to 2026
$22.3M
NCATS NIH HHS UM1 TR004538
6 · The paper itself

Abstract

introductionGout is an inflammatory arthritis that, when uncontrolled, can lead to chronic pain, disability, increased demand for healthcare, and poor health outcomes. This study sought to identify patients with gout and to describe the differences in epidemiology, pharmacotherapy, healthcare utilization, and outcomes for patients with controlled and uncontrolled gout in the United States (US) Veterans Affairs (VA) healthcare system.

methodsThis retrospective cohort study used electronic health record (EHR) data from VA patients from all US states and territories with gout from 1/1/2016 to 12/31/2022. The study included adult VA patients (18 +) with a diagnosis code for gout (ICD10 codes M10 or M1A) and two or more encounters 30 or more days apart. Uncontrolled gout was defined as one serum uric acid level (sUA) level > 8 mg/dl, tophi, or both in the study period.

resultsOf the 331,664 patients who met study criteria, 42% (138,068) were considered to have uncontrolled gout and 58% (193,596) were controlled. The uncontrolled group was younger (mean age 64 vs. 70 years, p < 0.01), and both groups were predominantly white non-Hispanic (58% and 70%) and male (99% and 99%). Specialist visits were more common in the uncontrolled group during follow-up: podiatry (38% vs. 30%, p < 0.01), rheumatology (24% vs. 9%, p < 0.01), and nephrology (24% vs. 12%, p < 0.01). Patients with uncontrolled gout were also significantly more likely to be seen in the emergency room (55% vs. 38%, p < 0.01) or admitted to the hospital (47% vs. 37%, p < 0.01) during follow-up.

conclusionsNearly half of VA patients with gout met criteria for uncontrolled gout, and these patients experienced greater healthcare utilization and worse health outcomes than patients with controlled gout. Patients with uncontrolled gout could benefit from additional/alternative approaches such as the adoption of a treat-to-target strategy and increasing referrals to a specialist.

Indexed as

GoutOutcomesPharmacotherapyTreatmentVeterans

Identifiers

PMID40971023
PMCPMC12638621

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.